ES2184150T3 - Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas. - Google Patents

Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas.

Info

Publication number
ES2184150T3
ES2184150T3 ES97954350T ES97954350T ES2184150T3 ES 2184150 T3 ES2184150 T3 ES 2184150T3 ES 97954350 T ES97954350 T ES 97954350T ES 97954350 T ES97954350 T ES 97954350T ES 2184150 T3 ES2184150 T3 ES 2184150T3
Authority
ES
Spain
Prior art keywords
aminometil
oxa
oct
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97954350T
Other languages
English (en)
Inventor
Uwe Petersen
Michael Matzke
Thomas Jaetsch
Thomas Schenke
Thomas Himmler
Stephan Bartel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2184150T3 publication Critical patent/ES2184150T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE LA QUINOLONA Y DERIVADOS DEL ACIDO NAFTIRIDON-CARBOXILICO QUE ESTAN SUSTITUIDOS EN LA POSICION 7 POR UN GRUPO 1-AMINOMETIL-2-OXA-7AZABICICLO[3.3.0.]OCT-7-ILO, Y A SUS SALES PARA EL TRATAMIENTO DE LAS INFECCIONES POR HELICOBACTER PYLORI Y DE LAS ENFERMEDADES GASTRODUODENALES ASOCIADAS A LAS MISMAS.
ES97954350T 1996-12-16 1997-12-03 Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas. Expired - Lifetime ES2184150T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19652219A DE19652219A1 (de) 1996-12-16 1996-12-16 Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen

Publications (1)

Publication Number Publication Date
ES2184150T3 true ES2184150T3 (es) 2003-04-01

Family

ID=7814821

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97954350T Expired - Lifetime ES2184150T3 (es) 1996-12-16 1997-12-03 Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas.

Country Status (8)

Country Link
US (2) US6288081B1 (es)
EP (1) EP0944385B1 (es)
JP (1) JP2001506242A (es)
AU (1) AU5853898A (es)
CA (1) CA2274892A1 (es)
DE (2) DE19652219A1 (es)
ES (1) ES2184150T3 (es)
WO (1) WO1998026768A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633805A1 (de) * 1996-02-23 1997-08-28 Bayer Ag Gegenenenfalls substituierte 8-Cyan-l-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre Derivate
DE19733243A1 (de) 1997-08-01 1999-02-04 Bayer Ag Verfahren zur Herstellung von 3-Cyano-2,4-dihalogen-5-fluor-benzoesäure
WO2000029369A1 (fr) * 1998-11-18 2000-05-25 Asahi Glass Company Ltd. Derives d'acide aminoacrylique et procede de production correspondant
AU2004206141A1 (en) * 2003-01-24 2004-08-05 Niva Shapira Synergistic compositions and methods for potentiating anti-oxidative activity
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
CN101263146B (zh) 2005-07-27 2012-12-05 艾其林医药公司 抗感染试剂8-甲氧基-9h-异噻唑并[5,4-b]喹啉-3,4-二酮及相关化合物
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4232172A1 (de) * 1992-09-25 1994-03-31 Bayer Ag 7-(Aminomethyl-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)chinolon- und Naphthyridoncarbonsäure-Derivate
DE4408212A1 (de) 1994-03-11 1995-09-14 Bayer Ag 5-Vinyl- und 5-Ethinyl-chinolon- und -naphthyridon-carbonsäuren
ATE209651T1 (de) 1996-02-27 2001-12-15 Dainippon Pharmaceutical Co Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung

Also Published As

Publication number Publication date
US6288081B1 (en) 2001-09-11
DE19652219A1 (de) 1998-06-18
EP0944385A2 (de) 1999-09-29
DE59708511D1 (de) 2002-11-21
AU5853898A (en) 1998-07-15
WO1998026768A3 (de) 1998-08-06
EP0944385B1 (de) 2002-10-16
JP2001506242A (ja) 2001-05-15
CA2274892A1 (en) 1998-06-25
US20010036941A1 (en) 2001-11-01
WO1998026768A2 (de) 1998-06-25

Similar Documents

Publication Publication Date Title
ES467828A1 (es) Un procedimiento para preparar nuevos compuestos de cefem y cefam
ES2175519T3 (es) Uso de derivados de acido7-(2-oxa-5,8-diazabiciclo(4,3,0)non-8-8-il)-quinoloncarboxilico y-naftiridoncarboxilico para la fabricacion de un medicanto para la terapia de infecciones por helicobacter pylori y las enfermedades gastroduodenales asociadas con ellas.
ES2084073T3 (es) Aclarados finales libres de cromo para metal fosfatado.
ES2081397T3 (es) O-metil derivados de azitromicina a, procedimiento y productos intermedios para su preparacion, y uso de los mismos en la preparacion de productos farmaceuticos.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
MX9306986A (es) Composiciones farmaceuticas a base de taxoides.
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
ES2056105T3 (es) Di-t-butilfenoles sustituidos.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2189782T3 (es) Derivados de pteridina opticamente activos.
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
ECSP034437A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ES2191090T3 (es) Nuevos compuestos heterociclicos.
ES2022704B3 (es) Procedimiento para la obtencion de preparaciones colorantes acuosas concentradas de colorantes organicos.
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
AR241082A1 (es) Nuevos derivados de pirazol utiles como agentes herbicidas, las composiciones herbicidas que los contienen y los procedimientos para producir estos derivados de pirazol".
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2053511T3 (es) Derivados de acidos aminocarboxilicos biciclicos, procedimiento y productos intermedios para su preparacion, asi como su empleo.
ES2054738T3 (es) Derivados de acido 3-desmetil-4-fluoromevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su empleo y productos intermedios.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.